Core Viewpoint - Savara Inc. is facing a class action securities lawsuit due to alleged securities fraud that affected investors between March 4, 2024, and May 23, 2025 [1] Group 1: Lawsuit Details - The lawsuit claims that Savara Inc. made false statements regarding the MOLBREEVI Biologics License Application (BLA) for treating pulmonary alveolar proteinosis, indicating insufficient information about its chemistry, manufacturing, and controls [2] - It is alleged that the FDA was unlikely to approve the MOLBREEVI BLA in its current form, which would delay Savara's submission timeline and increase the need for additional capital [2] Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until November 7, 2025, to request to be appointed as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Group 3: Legal Representation - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years and consistently ranking among the top securities litigation firms in the U.S. [4]

Core Viewpoint - Savara Inc. has announced the promotion of Dr. Yasmine Wasfi to Chief Medical Officer (CMO), effective immediately, succeeding Dr. Ray Pratt who will become Senior Medical Advisor [1] Company Summary - Savara Inc. is a clinical stage biopharmaceutical company focused on rare respiratory diseases [1] - Dr. Wasfi will report directly to the Company's Chair and Chief Executive Officer and will be part of the executive leadership team [1]

Core Viewpoint - Savara Inc. is facing a class action lawsuit due to allegations of issuing materially false and misleading statements regarding its drug MOLBREEVI, which is intended for the treatment of pulmonary alveolar proteinosis [3]. Group 1: Allegations and Class Period - The class period for the lawsuit is from March 4, 2024, to May 23, 2025 [3]. - Allegations include that Savara failed to disclose critical information about MOLBREEVI's chemistry, manufacturing, and controls, leading to doubts about FDA approval [3]. - The lawsuit claims that the delay in regulatory approval would likely necessitate Savara to raise additional capital [3]. Group 2: Shareholder Actions - Shareholders who purchased SVRA shares during the class period are encouraged to register for the class action, with a deadline of November 7, 2025, to seek lead plaintiff status [4]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the case lifecycle [4]. Group 3: Law Firm Information - The Gross Law Firm is representing the shareholders and is recognized for protecting investors' rights against deceit and fraud [5]. - The firm emphasizes its commitment to responsible business practices and seeks recovery for investors affected by misleading statements [5].

Core Viewpoint - Savara Inc. is facing a class action lawsuit due to alleged securities fraud following the FDA's refusal to file letter regarding its MOLBREEVI BLA, which led to a significant drop in share price [3][4]. Group 1: Company Announcement - On May 27, 2025, Savara announced that it received a refusal to file letter from the FDA for the MOLBREEVI BLA, indicating that the submission was not sufficiently complete for review [3]. - Following this announcement, Savara's share price fell by $0.90, or approximately 31.69%, from $2.84 on May 23, 2025, to $1.94 on May 27, 2025 [3]. Group 2: Lawsuit Details - The lawsuit is on behalf of investors who purchased securities between March 7, 2024, and May 23, 2025, alleging that Savara made false or misleading statements regarding the MOLBREEVI BLA [4]. - Specific allegations include that the MOLBREEVI BLA lacked sufficient information on chemistry, manufacturing, and controls, making FDA approval unlikely in its current form [4]. - The lawsuit also claims that the delay in regulatory approval increased the likelihood of Savara needing to raise additional capital [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Savara Inc. securities during the specified class period of the upcoming lead plaintiff deadline on November 7, 2025, and the potential for compensation through a contingency fee arrangement [1][2]. Group 1: Class Action Details - Investors who bought Savara securities between March 7, 2024, and May 23, 2025, may be eligible for compensation without upfront costs [1]. - A class action lawsuit has already been filed, and interested parties must act by the November 7, 2025 deadline to serve as lead plaintiff [2]. - The lawsuit alleges that Savara made false or misleading statements regarding the approval process of its drug MOLBREEVI, impacting investor decisions [4]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in this area [3]. - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time, and has consistently ranked highly in terms of settlements since 2013 [3]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [3].

Core Viewpoint - A class action lawsuit has been filed against Savara Inc. for failing to disclose critical information regarding the MOLBREEVI Biologics License Application, leading to significant investor losses [8]. Allegation Details - The lawsuit claims that during the class period from March 7, 2024, to May 23, 2025, Savara did not disclose that the MOLBREEVI BLA lacked sufficient information on chemistry, manufacturing, and controls, making FDA approval unlikely [8]. - The complaint also states that the delay in regulatory approval would likely necessitate Savara to raise additional capital [8]. - Following the announcement of a refusal to file letter from the FDA on May 27, 2025, Savara's stock price dropped by $0.90, or 31.69%, closing at $1.94 per share [8]. Next Steps - Investors who purchased Savara shares and suffered losses are encouraged to contact the law firm for more information and to discuss their legal rights [4]. - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is November 7, 2025 [8]. About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in complex litigation across the United States [5].

Core Viewpoint - The Gross Law Firm is notifying shareholders of Savara Inc. regarding a class action lawsuit related to misleading statements and omissions concerning the company's drug application for MOLBREEVI, which may have impacted stock value [1][3]. Group 1: Allegations - The complaint alleges that during the class period from March 4, 2024, to May 23, 2025, Savara Inc. made materially false and misleading statements regarding the MOLBREEVI BLA, particularly about its chemistry, manufacturing, and controls [3]. - It is claimed that the FDA was unlikely to approve the MOLBREEVI BLA in its current form, which would delay Savara's submission timeline and increase the need for additional capital [3]. Group 2: Class Action Details - Shareholders who purchased shares of SVRA during the specified class period are encouraged to register for the class action, with a deadline of November 7, 2025, to seek lead plaintiff status [4]. - Participants will be enrolled in a portfolio monitoring software to receive updates on the case's progress, with no cost or obligation to participate [4]. Group 3: Law Firm's Mission - The Gross Law Firm aims to protect investors' rights against deceit, fraud, and illegal business practices, emphasizing the importance of responsible corporate behavior [5].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Savara Inc. regarding a class action lawsuit related to misleading statements and omissions concerning the company's drug application for MOLBREEVI, which is intended for treating pulmonary alveolar proteinosis [1][2]. Group 1: Allegations and Class Period - The class period for the allegations is from March 4, 2024, to May 23, 2025 [1]. - Allegations include that Savara's statements about the MOLBREEVI Biologics License Application (BLA) were materially false and misleading, particularly regarding the lack of sufficient information on the drug's chemistry, manufacturing, and controls [1]. - It is claimed that the FDA was unlikely to approve the MOLBREEVI BLA in its current form, which would delay the submission timeline previously communicated to investors [1]. Group 2: Impact on Company and Shareholders - The delay in regulatory approval for MOLBREEVI increases the likelihood that Savara would need to raise additional capital [1]. - Shareholders who purchased shares during the class period are encouraged to register for the class action, with a deadline to seek lead plaintiff status set for November 7, 2025 [2]. - Participants in the class action will be enrolled in a portfolio monitoring software to receive updates on the case [2]. Group 3: Law Firm's Commitment - The Gross Law Firm is recognized for protecting investors' rights against deceit and fraud, emphasizing the importance of responsible business practices [3]. - The firm aims to recover losses for investors caused by misleading statements or omissions that led to artificial inflation of the company's stock [3].

Core Viewpoint - A class action lawsuit has been filed against Savara Inc. for failing to disclose critical information regarding the MOLBREEVI Biologics License Application, leading to significant investor losses [8]. Allegation Details - The lawsuit claims that during the class period from March 7, 2024, to May 23, 2025, Savara did not disclose that the MOLBREEVI BLA lacked sufficient information on chemistry, manufacturing, and controls, making FDA approval unlikely [8]. - The complaint also states that the delay in regulatory approval would likely necessitate Savara to raise additional capital [8]. - Following the announcement of a refusal to file letter from the FDA on May 27, 2025, Savara's stock price dropped by $0.90, or 31.69%, closing at $1.94 per share [8]. Next Steps - Investors who purchased Savara shares during the class period and suffered losses are encouraged to contact the law firm for more information and to discuss their legal rights [4]. - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is November 7, 2025 [8]. About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in complex litigation [5]. - The firm has offices in New York, California, and South Carolina, and specializes in commercial and securities litigation [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Savara Inc. securities between March 7, 2024, and May 23, 2025, of the upcoming lead plaintiff deadline on November 7, 2025, for a class action lawsuit [1] Group 1: Class Action Details - Investors who bought Savara securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [2][5] - The lead plaintiff must file a motion with the court by November 7, 2025, to represent other class members in the litigation [2] Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [3] - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time, and has consistently ranked highly in securities class action settlements [3] - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [3] Group 3: Case Allegations - The lawsuit alleges that Savara's defendants made false or misleading statements regarding the MOLBREEVI Biologics License Application, which lacked sufficient information for FDA approval [4] - It is claimed that the delay in regulatory approval increased the likelihood of Savara needing to raise additional capital, contradicting prior public statements made by the company [4] - The lawsuit asserts that when the true information became public, investors suffered damages due to the misleading nature of the defendants' statements [4]